Lawrence Rice, MD

Dottie and Jimmy C. Adair Distinguished Chair in Hematology, Department of Medicine
Professor of Medicine, Institute for Academic Medicine
Full Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


After completing an Internal Medicine Internship, Residency, and Hematology fellowship at Baylor College of Medicine, Dr. Rice was appointed to the faculty and became a Professor of Medicine and Professor of Thrombosis Research. For more than 20 years, he served as the Hematology Program Director and Director of the required medical student Hematology/Oncology course.

In 2007, his primary affiliation changed to Chief of Hematology at Houston Methodist Hospital and Professor of Medicine at Weill Cornell Medical College. He has maintained an active Consultative Hematology practice at Houston Methodist for more than 30 years. This program is distinguished by the depth and breadth of the blood disorders managed, including Congenital TTP, paroxysmal nocturnal hemoglobinuria and Evans' syndrome. Two-thirds of his patients have "benign" hematologic disorders and one-third have hematologic malignancies.

Dr. Rice actively teaches medical students, residents and subspecialty fellows, and has received numerous teaching awards, including induction in the inaugural class of the Baylor Medicine Educator Hall of Fame. In 2009-2010, he received the Edward C. Lynch Outstanding Teacher Award from Houston Methodist Internal Medicine residents, the Houston Methodist GME Teacher of the Year Award, the Hematology Honorary Fellow (Outstanding Teacher) Award from graduating MD Anderson Hematology/Oncology fellows, and the Hematology Educator of the Year from Baylor Hematology/Oncology fellows. Dr. Rice frequently gives lectures and chairs national educational symposia and CME events.

Description of Research

Dr. Rice's research interests include:

-Thrombocytopenic disorders (ITP, TTP and HIT)
-Bleeding, clotting and anticoagulation problems
-Anemias, erythropoietin actions and iron metabolism
Recent clinical studies include participation in pivotal trials of novel platelet-stimulating hormones, anticoagulants, and iron-chelators.

Areas Of Expertise

Hematology Anemias Thrombocytopenias Anticoagulants Erythropoietin
Education & Training

, Baylor College of Medicine
, Emory University

Primary thyroid lymphoma presenting as dermatomyositis: A first case and review of the literature
Nan, X, Adike, A, Rice, L & Bunin, VM 2016, BMJ Case Reports, vol 2016, 215057. DOI:

A need for a systematic genetic evaluation of hereditary polyuric patients
Bichet, DG, Rice, L & Levallois-Gignac, J 2016, Clinical Kidney Journal, vol 9, no. 2, pp. 177-179. DOI:

How low is too low: Statin induced hemolysis
Pacheco, JM, Yilmaz, M & Rice, L 2016, American Journal of Hematology, vol 91, no. 2, pp. 267. DOI:

Polycythemia vera: An appraisal of the biology and management 10 years after the discovery of JAK2 V617F
Stein, BL, Oh, ST, Berenzon, D, Hobbs, GS, Kremyanskaya, M, Rampal, RK, Abboud, CN, Adler, K, Heaney, ML, Jabbour, EJ, Komrokji, RS, Moliterno, AR, Ritchie, EK, Rice, L, Mascarenhas, J & Hoffman, R 2015, Journal of Clinical Oncology, vol 33, no. 33, pp. 3953-3960. DOI:

There is no such thing as a "positive" antibody test: Diagnosing heparin-induced thrombocytopenia in 2015
Rice, L 2015, Chest, vol 148, no. 1, pp. 1-3. DOI:

Sickle cell patients face death in the ICU
Rice, L & Teruya, M 2014, Critical Care Medicine, vol 42, no. 7, pp. 1730-1731. DOI:

Progressive anemia and left upper quadrant pain in a patient with polycythemia vera
Roberts, JA, Morales, M & Rice, L 2014, JAMA: The Journal of the American Medical Association, vol 311, no. 21, pp. 2227-2228. DOI:

Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis
Meyers, DE, Adu-Gyamfi, B, Segura, AM, Buja, LM, Mallidi, HR, Frazier, OH & Rice, L 2013, American Journal of Transplantation, vol 13, no. 10, pp. 2730-2733. DOI:

Successful long-term treatment of philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide
Ahn, IE, Natelson, E & Rice, L 2013, Clinical Lymphoma, Myeloma and Leukemia, vol 13, no. SUPPL. 2. DOI:

PF4/heparin antibody testing and treatment of heparin-induced thrombocytopenia in the intensive care unit
Wanat, M, Fitousis, K, Hall, J & Rice, L 2013, Clinical and Applied Thrombosis/Hemostasis, vol 19, no. 3, pp. 297-302. DOI:

The amyloidoses: clinical features, diagnosis and treatment.
Baker, KR & Rice, L 2012, Houston Methodist DeBakey Cardiovascular Journal, vol 8, no. 3, pp. 3-7.

Amyloidosis: changing approaches and outcomes.
Rice, L & Baker, KR 2012, Houston Methodist DeBakey Cardiovascular Journal, vol 8, no. 3.

"Surgical" Abdomen in a Patient with Chronic Lymphocytic Leukemia: A Case of Acquired Angioedema
Jung, M & Rice, L 2011, Journal of Gastrointestinal Surgery, vol 15, no. 12, pp. 2262-2266. DOI:

Heparin-induced thrombocytopenia in the cardiac patient: 10 points to help the physician.
Rice, L 2011, Houston Methodist DeBakey Cardiovascular Journal, vol 7, no. 4, pp. 6-9.

Unusual autoimmune nonhematologic complications in chronic lymphocytic leukemia
Jung, M & Rice, L 2011, Clinical Lymphoma, Myeloma and Leukemia, vol 11, no. SUPPL.1. DOI:

A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT study
Boyce, SW, Bandyk, DF, Bartholomew, JR, Frame, JN & Rice, L 2011, American Journal of Therapeutics, vol 18, no. 1, pp. 14-22. DOI:

The HIT Expert Probability (HEP) Score: A novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion
Cuker, A, Arepally, G, Crowther, MA, Rice, L, Datko, F, Hook, K, Propert, KJ, Kuter, DJ, Ortel, TL, Konkle, BA & Cines, DB 2010, Journal of Thrombosis and Haemostasis, vol 8, no. 12, pp. 2642-2650. DOI:

Rationale and design of the PREVENT-HIT study: A randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis
Frame, JN, Rice, L, Bartholomew, JR & Whelton, A 2010, Clinical Therapeutics, vol 32, no. 4, pp. 626-636. DOI:

Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition
Wen, J, Feng, Y, Huang, W, Chen, H, Liao, B, Rice, L, Preti, HA, Kamble, RT, Zu, Y, Ballon, DJ & Chang, CC 2010, Leukemia Research, vol 34, no. 1, pp. 85-92. DOI:

Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: A computer-assisted image analysis study
Ahmed, A, Powers, MP, Youker, KA, Rice, L, Ewton, A, Dunphy, CH & Chang, CC 2009, Pathology Research and Practice, vol 205, no. 9, pp. 634-638. DOI: